CardiaCare offers a non-invasive neuromodulation device that applies electrical stimulation to the wrist to manage atrial fibrillation (AF) symptoms and reduce recurrence rates. By utilizing closed-loop monitoring and machine learning algorithms, the system personalizes therapy based on real-time cardiac data, improving patient outcomes and quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Atrial fibrillation (AF) affects millions worldwide and is associated with increased stroke risk and reduced quality of life. Current treatments like cardioversion and ablation often have high failure rates, leading to recurrent episodes, hospitalizations, and additional procedures.
Solution
CardiaCare offers a non-invasive neuromodulation therapy delivered via a wrist-worn wearable to reduce AF episodes and symptoms. The system uses closed-loop monitoring with optical and electrical (ECG) sensors to acquire patient-specific cardiac data. This data is then transmitted to a secure cloud server where proprietary machine learning algorithms generate personalized neuromodulation therapy. The therapy utilizes median-vagus nerve stimulation (mVNS) to balance the sympathetic and vagal nerve control over heart rate and rhythm, augmenting central nervous system balance and reducing precursors to AF.
Target Audience
The primary target audience includes individuals diagnosed with atrial fibrillation seeking non-invasive alternatives or adjunctive therapies to manage their condition and reduce AF burden.
Features
- Non-invasive electrical neuromodulation applied at the wrist
- Closed-loop monitoring using optical and ECG sensors
- Personalized therapy generated by machine learning algorithms
- Cloud-based health platform with a large AF-specific patient database
- Reduction of AF recurrence rates and related symptoms
- mVNS (median-vagus nerve stimulation) technology
- Mobile app for data transfer and therapy management